Head-to-head evidence
Donanemab vs Remternetug
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
Donanemab · Kisunla
Marketed by Eli Lilly
NCT05108922 · Phase 3 · completed
Participants were randomized to donanemab or active-control aducanumab, but the trial was open-label rather than blinded. Both prespecified primary amyloid-clearance comparisons favored donanemab with statistically significant results; the biomarker-based primary endpoint and lack of blinding support a moderate evidence grade rather than a strong one.
Next expected readout: November 2027 · NCT05026866 (registry estimate)
Remternetug
Developed by Eli Lilly
NCT05463731 · Phase 3 · completed
The study randomized 1,667 participants to remternetug or matching placebo, with participants and investigators blinded during the main treatment period. Its primary endpoint was amyloid plaque clearance measured by PET, a biomarker endpoint, and the registry does not report whether the week-52 comparison was favorable or statistically significant.
Next expected readout: April 2029 · NCT06653153 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Donanemab's landscape · Remternetug's landscape